Literature DB >> 12721928

Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues.

Robert P Pless1, Adwoa D Bentsi-Enchill, Philippe Duclos.   

Abstract

In the planning and implementation of mass immunization campaigns, vaccine delivery has always been a priority. However, safety issues have gained increasingly more attention and grown in importance, and campaign planners must now take them into prime consideration. The World Health Organization has released guidelines to assist with the design and implementation of safety surveillance systems, primarily for developing countries, and these include a new monograph for measles mass campaigns. Experience in the past decade with mass campaigns (primarily in developed countries) shows that measles vaccine performs in these settings as anticipated from pre- and post-licensure studies. Serious adverse events are rare, even under the increased scrutiny extended during a campaign. The experience in developing country settings is growing. The implementation of safety surveillance for mass campaigns offers a unique opportunity for countries to avoid crisis situations and to begin vaccine safety monitoring in routine immunization programs.

Mesh:

Substances:

Year:  2003        PMID: 12721928     DOI: 10.1086/368049

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  8 in total

1.  Measles vector as a multigene delivery platform facilitating iPSC reprogramming.

Authors:  Qi Wang; Alanna Vossen; Yasuhiro Ikeda; Patricia Devaux
Journal:  Gene Ther       Date:  2019-02-04       Impact factor: 5.250

2.  Protective anti-hepatitis B virus responses in rhesus monkeys primed with a vectored measles virus and boosted with a single dose of hepatitis B surface antigen.

Authors:  Jorge Reyes-del Valle; Gregory Hodge; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2009-06-17       Impact factor: 5.103

3.  A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.

Authors:  Jorge Reyes del Valle; Patricia Devaux; Gregory Hodge; Nicholas J Wegner; Michael B McChesney; Roberto Cattaneo
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

4.  Nuclear reprogramming with a non-integrating human RNA virus.

Authors:  Christopher B Driscoll; Jason M Tonne; Moustafa El Khatib; Roberto Cattaneo; Yasuhiro Ikeda; Patricia Devaux
Journal:  Stem Cell Res Ther       Date:  2015-03-26       Impact factor: 6.832

5.  Mobilize to vaccinate: lessons learned from social mobilization for immunization in low and middle-income countries.

Authors:  Mohamed F Jalloh; Elisabeth Wilhelm; Neetu Abad; Dimitri Prybylski
Journal:  Hum Vaccin Immunother       Date:  2019-10-29       Impact factor: 3.452

Review 6.  Highly affordable vaccines are critical for our continued efforts to reduce global childhood mortality.

Authors:  Stefan H E Kaufmann
Journal:  Hum Vaccin Immunother       Date:  2019-05-17       Impact factor: 3.452

Review 7.  A review of the safety and efficacy of current COVID-19 vaccines.

Authors:  Zehong Huang; Yingying Su; Tianying Zhang; Ningshao Xia
Journal:  Front Med       Date:  2022-02-03       Impact factor: 9.927

8.  Mass Measles Vaccination Campaign in Aila Cyclone-Affected Areas of West Bengal, India: An In-depth Analysis and Experiences.

Authors:  Sarmila Mallik; Pankaj Kumar Mandal; Pramit Ghosh; Nirmalya Manna; Chitra Chatterjee; Debadatta Chakrabarty; Saumendra Nath Bagchi; Samir Dasgupta
Journal:  Iran J Med Sci       Date:  2011-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.